Sköldunger Anders, Fastbom Johan, Wimo Anders, Fratiglioni Laura, Johnell Kristina
Aging Research Center, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden.
Bollebergsvägen, 5, 820 70, Bergsjö, Sweden.
BMC Neurol. 2016 Feb 29;16:28. doi: 10.1186/s12883-016-0547-x.
We aimed to investigate the impact of dementia on drug costs in older people, after adjustment for socio-demographic factors, residential setting and co-morbidities.
We included 4,129 individuals aged ≥ 60 years from The Swedish National Study on Aging and Care (SNAC) in Kungsholmen and Nordanstig 2001-2004. A generalized linear model (GLM) was used to investigate how much dementia was associated with drug costs.
Overall drug costs for persons with and without dementia were 6147 SEK (816 USD) and 3810 SEK (506 USD), respectively. The highest drug cost was observed for nervous system drugs among persons with dementia. The adjusted GLM showed that dementia was not associated with higher overall drug costs (β = 1.119; ns). Comorbidities and residential setting were the most important factors for overall drug costs.
We found that the observed higher overall drug costs for persons with dementia were due to comorbidities and residential setting.
我们旨在研究在对社会人口统计学因素、居住环境和合并症进行调整后，痴呆症对老年人药物费用的影响。
我们纳入了2001年至2004年来自斯德哥尔摩市国王岛和诺尔达斯蒂格的瑞典全国老龄化与护理研究（SNAC）中4129名年龄≥60岁的个体。使用广义线性模型（GLM）来研究痴呆症与药物费用之间的关联程度。
患有痴呆症和未患痴呆症的人的总体药物费用分别为6147瑞典克朗（816美元）和3810瑞典克朗（506美元）。在患有痴呆症的人群中，神经系统药物的费用最高。调整后的GLM显示，痴呆症与较高的总体药物费用无关（β = 1.119；无显著性差异）。合并症和居住环境是总体药物费用的最重要因素。
我们发现，观察到的患有痴呆症的人总体药物费用较高是由于合并症和居住环境所致。
